JAK2 inhibitor in combination with IM is more effective in reducing JAK2/STAT5 activity and inhibiting proliferative capacity of IM-insensitive CML cells. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.